- Our World
- Our Business
- Life at Lupin
- Global Sites
HEADQUARTERED IN MUMBAI, INDIA, LUPIN LIMITED TODAY IS AN INNOVATION LED TRANSNATIONAL PHARMACEUTICAL COMPANY PRODUCING A WIDE RANGE OF QUALITY, AFFORDABLE GENERIC AND BRANDED FORMULATIONS AND APIs FOR THE DEVELOPED AND DEVELOPING MARKETS OF THE WORLD.
Dr. Desh Bandhu Gupta's vision and dream to fight life threatening infectious diseases and to manufacture drugs of the highest social priority led to the formation of Lupin in the year 1968. His Vision, his inimitable commitment and verve have steered Lupin to achieving the distinction of becoming one of the fastest growing Generic pharmaceutical companies globally. Lupin first gained recognition when it became one of the world's largest manufacturers of Tuberculosis drugs. The Company today has significant market share in key markets in the Cardiovascular (prils and statins), Diabetology, Asthma, Pediatrics, CNS, GI, Anti-Infectives and NSAIDs therapy segments, not to mention global leadership positions in the Anti-TB and Cephalosporins segments. segments.
The Company's R&D endeavours have resulted in significant progress in its NCE program. The Company's foray into Advanced Drug Delivery Systems has resulted in the development of platform technologies that are being used to develop value-added generic pharmaceuticals. Lupin's world class manufacturing facilities, spread across India and Japan, have played a critical role in enabling the companies realize its global aspirations. Benchmarked to International standards, these facilities are approved by international regulatory agencies like US FDA, UK MHRA, Japan's MHLW, TGA Australia, WHO, and the MCC South Africa. Our Drugs and products reach over 100 countries in the world.
Lupin is the 5 th largest and fastest growing top 10 generics player in the US (5.6% market share by prescriptions, IMS Health, September 2015) and the 2 nd largest Indian pharmaceutical company by market capitalization. The Company is also the 9 th largest generic pharmaceutical player in Japan and the 4 th largest generic pharmaceutical company in South Africa (IMS Health, March 2016). For the financial year ended 31 st March 2016, Lupin's Consolidated turnover and Profit after Tax stood at Rs. 137,016 million (USD 2.09 billion) and Rs. 22,707 million (USD 347 million) respectively.